{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"OGN","limit":50},"count":50,"signals":[{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":23,"context":"tively affect sales of existing products and could result in the payment of royalties or in the recognition of an impairment charge with respect to intangible assets associated with certain products. Competitive pressures continue to intensify as the industry grows. -12- [Table of Contents](#i5502f7269489448b836b31d55fc86e63_205) To remain competitive, we must dedicate resources to quality control, flexibility to mee","filed_date":"2026-02-24","accession":"0001628280-26-011125","full_text":"https://origin.rootz.global/static/filing/0001628280-26-011125.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":54,"context":"uch as patient adherence programs that can further drive value in collaboration with our trade partners. We do not have any single customer that, if such customer were lost, would be likely to have a material adverse effect on our business. -9- [Table of Contents](#i5502f7269489448b836b31d55fc86e63_205) Distribution Our global network enables us to distribute products directly and indirectly to patients in more than 140","filed_date":"2026-02-24","accession":"0001628280-26-011125","full_text":"https://origin.rootz.global/static/filing/0001628280-26-011125.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"ion policies and programs and concluded that our executive and non-executive compensation programs do not encourage excessive or unnecessary risk taking, and any inherent risks are unlikely to have a material adverse effect on us. The next review and assessment of our compensation policies and programs will be conducted in fiscal year 2025. 69 Talent Committee Report  Our Talent Committee has reviewed and discussed the","filed_date":"2025-04-25","accession":"0000950170-25-058795","full_text":"https://origin.rootz.global/static/filing/0000950170-25-058795.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":32,"context":"tors named in the accompanying proxy statement to hold office for a one-year term until the 2026 Annual Meeting of Shareholders;  Approval, on a non-binding advisory basis, of the compensation of our named executive officers;  Approval of an amendment and restatement of the Organon & Co. 2021 Incentive Stock Plan; Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounti","filed_date":"2025-04-25","accession":"0000950170-25-058795","full_text":"https://origin.rootz.global/static/filing/0000950170-25-058795.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":18,"context":"tively affect sales of existing products and could result in the payment of royalties or in the recognition of an impairment charge with respect to intangible assets associated with certain products. Competitive pressures continue to intensify as the industry grows. To remain competitive, the additional resources required to meet market challenges include quality control, flexibility to meet buyer specifications, an","filed_date":"2025-02-28","accession":"0001821825-25-000006","full_text":"https://origin.rootz.global/static/filing/0001821825-25-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":49,"context":"uch as patient adherence programs that can further drive value in collaboration with our trade partners. We do not have any single customer that, if such customer were lost, would be likely to have a material adverse effect on our business. Distribution Our global network enables us to distribute products directly and indirectly to patients in more than 140 countries and territories, including through our regional distr","filed_date":"2025-02-28","accession":"0001821825-25-000006","full_text":"https://origin.rootz.global/static/filing/0001821825-25-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":38,"context":"ats as private or confidential. 5 Companys Knowledge means the actual knowledge of each Person set forth on Section 1.1(a) of the Company Disclosure Schedule, after making reasonable inquiry. Company Material Adverse Effect means any change, event, circumstance, occurrence, effect, state of facts or development that has had or would reasonably be expected to have, individually or in the aggregate, a material adverse eff","filed_date":"2024-09-23","accession":"0001104659-24-102053","full_text":"https://origin.rootz.global/static/filing/0001104659-24-102053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":53,"context":"ach or contravention or payment (but not creation of Liens) referred to in clause (2)(i), to the extent that such conflict, breach, contravention or payment could not reasonably be expected to have a Material Adverse Effect. (d)No material approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection wi","filed_date":"2024-05-17","accession":"0001104659-24-063008","full_text":"https://origin.rootz.global/static/filing/0001104659-24-063008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"nd does not believe that our executive and non-executive compensation programs encourage excessive or unnecessary risk taking, and any risk inherent in our compensation programs is unlikely to have a material adverse effect on us.  Talent Committee Report  Our Talent Committee has reviewed and discussed the section entitled Compensation Discussion and Analysis with our management. Based upon this review and discussion,","filed_date":"2024-04-25","accession":"0001193125-24-114048","full_text":"https://origin.rootz.global/static/filing/0001193125-24-114048.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":26,"context":"n the accompanying proxy statement to hold office for a one-year term until the 2025 Annual Meeting of Shareholders; | | |  |  |  Approval, on a non-binding advisory basis, of the compensation of our named executive officers; | | |  |  |  Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2024; and | | |  |  |  Consideration of such other business as ma","filed_date":"2024-04-25","accession":"0001193125-24-114048","full_text":"https://origin.rootz.global/static/filing/0001193125-24-114048.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":19,"context":"tively affect sales of existing products and could result in the payment of royalties or in the recognition of an impairment charge with respect to intangible assets associated with certain products. Competitive pressures continue to intensify as the industry grows. To remain competitive, the additional resources required to meet market challenges include quality control, flexibility to meet buyer specifications, an","filed_date":"2024-02-26","accession":"0001628280-24-006733","full_text":"https://origin.rootz.global/static/filing/0001628280-24-006733.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":39,"context":"nt services such as patient adherence programs that can further drive value in collaboration with our trade partners. We do not have any single customer that, if such customer were lost, would have a material adverse effect on our business. Distribution Our global network enables us to distribute products directly and indirectly to patients in more than 140 countries and territories, including through our regional distr","filed_date":"2024-02-26","accession":"0001628280-24-006733","full_text":"https://origin.rootz.global/static/filing/0001628280-24-006733.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":52,"context":"Amendment No. 1 Effective Date (or true and correct in all material respects as of a specified date, if earlier); *provided* that any representation and warranty that is qualified as to materiality, Material Adverse Effect or similar language shall be true and correct (after giving effect to any qualification therein) in all respects. SECTION 6. Representations and Warranties. Each Loan Party represents and warrants to","filed_date":"2023-07-07","accession":"0001104659-23-079109","full_text":"https://origin.rootz.global/static/filing/0001104659-23-079109.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"rnance |  |  |  9 |  | | |  |  | | |  Boards Role in Strategic Planning |  |  |  9 |  | | |  |  | | |  Risk Oversight |  |  |  9 |  | | |  |  | | |  Board Oversight of Information Security, Including Cybersecurity and Data Privacy |  |  |  11 |  | | |  |  | | |  Independence of Directors |  |  |  11 |  | | |  |  | | |  Related Person Transactions |  |  |  12 |  | | |  |  | | |  Board Leadership Structu","filed_date":"2023-04-27","accession":"0001193125-23-122171","full_text":"https://origin.rootz.global/static/filing/0001193125-23-122171.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":25,"context":"r of double-digit growth Our fertility portfolio grew 9% We expanded our portfolio with the reacquisition of rights to combined oral contraceptives Marvelon and Mercilon in certain markets in Asia We entered into a licensing agreement for Xaciato, an FDA-approved treatment for bacterial vaginosis in females 12 years and older We entered into a research collaboration with Cirqle Biomedical for a preclinical, non-hormonal contracept","filed_date":"2023-04-27","accession":"0001193125-23-122171","full_text":"https://origin.rootz.global/static/filing/0001193125-23-122171.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":13,"context":"esearch and development | | | | | | | 471 | | | 339 | | | 210 | | 39 | | | 61 | | | | Acquired in-process research and development and milestones | | | | | | | 107 | | | 104 | | | | | 3 | | | * | | | Restructuring costs | | | | | | | 28 | | | 3 | | | 60 | | * | | (95) | | | | Interest expense | | | | | | | 422 | | | 258 | | | | | 64 | | | * | | | Exchange losses | | | | | | | 11 | | | 4 | | | 44 | | * | | (91) | | |","filed_date":"2023-02-27","accession":"0001821825-23-000003","full_text":"https://origin.rootz.global/static/filing/0001821825-23-000003.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":100,"match_count":13,"context":"elements across Organon's supply chain. Organon's manufacturing network and supply chains are designed to provide it with a flexible and scalable global platform for continued expansion, including in emerging markets. Organon believes its extensive manufacturing and supply chain expertise and capabilities positions it well to provide critical therapies for distribution worldwide and to meet growing demand over t","filed_date":"2023-02-27","accession":"0001821825-23-000003","full_text":"https://origin.rootz.global/static/filing/0001821825-23-000003.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":23,"context":"tively affect sales of existing products and could result in the payment of royalties or in the recognition of an impairment charge with respect to intangible assets associated with certain products. Competitive pressures have intensified as pressures in the industry have grown. To remain competitive, the additional resources required to meet market challenges include quality control, flexibility to meet buyer specif","filed_date":"2023-02-27","accession":"0001821825-23-000003","full_text":"https://origin.rootz.global/static/filing/0001821825-23-000003.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"uch as patient adherence programs that can further drive value in collaboration with Organon's trade partners. Organon does not have any single customer that, if such customer were lost, would have a material adverse effect on Organon's business. Distribution Organon's global network enables it to distribute products directly and indirectly to patients in more than 140 countries and territories, including through Organo","filed_date":"2023-02-27","accession":"0001821825-23-000003","full_text":"https://origin.rootz.global/static/filing/0001821825-23-000003.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"orate Governance |  |  |  7 |  | | |  Boards Role in Strategic Planning |  |  |  7 |  | | |  |  | | |  Risk Oversight |  |  |  7 |  | | |  |  | | |  Board Oversight of Information Security, Including Cybersecurity and Data Privacy |  |  |  9 |  | | |  |  | | |  Independence of Directors |  |  |  9 |  | | |  |  | | |  Related Person Transactions |  |  |  10 |  | | |  |  | | |  Board Leadership Structure","filed_date":"2022-04-28","accession":"0001193125-22-127598","full_text":"https://origin.rootz.global/static/filing/0001193125-22-127598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":31,"context":"lass I directors named in the accompanying proxy statement to hold office until the 2025 annual meeting of shareholders; | | |  |  |  Approve, on a non-binding advisory basis, the compensation of our Named Executive Officers; | | |  |  |  Approve, on a non-binding advisory basis, the frequency of future votes to approve the compensation of our Named Executive Officers; | | |  |  |  Ratify the appointment of Pricewaterho","filed_date":"2022-04-28","accession":"0001193125-22-127598","full_text":"https://origin.rootz.global/static/filing/0001193125-22-127598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":15,"context":"$ | 2,274 | | | | Selling, general and administrative | 1,668 | | | 23 | % | | 1,356 | | | (6) | % | | 1,443 | | | | Research and development | 443 | | | 111 | % | | 210 | | | (5) | % | | 220 | | | | Restructuring costs | 3 | | | * | | 60 | | | * | | 78 | | | | Other (income) expense, net | 279 | | | * | | 35 | | | * | | 66 | | | | | $ | 4,775 | | | 26 | % | | $ | 3,780 | | | (7) | % | | $ | 4,081 | | | * Calculatio","filed_date":"2022-03-21","accession":"0001821825-22-000002","full_text":"https://origin.rootz.global/static/filing/0001821825-22-000002.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":100,"match_count":14,"context":"elements across Organon's supply chain. Organon's manufacturing network and supply chains are designed to provide it with a flexible and scalable global platform for continued expansion, including in emerging markets. Organon believes its extensive manufacturing and supply chain expertise and capabilities positions it well to provide critical therapies for distribution worldwide and to meet growing demand over t","filed_date":"2022-03-21","accession":"0001821825-22-000002","full_text":"https://origin.rootz.global/static/filing/0001821825-22-000002.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":100,"match_count":25,"context":"tively affect sales of existing products and could result in the payment of royalties or in the recognition of an impairment charge with respect to intangible assets associated with certain products. Competitive pressures have intensified as pressures in the industry have grown. To remain competitive, the additional resources required to meet market challenges include quality control, flexibility to meet buyer specif","filed_date":"2022-03-21","accession":"0001821825-22-000002","full_text":"https://origin.rootz.global/static/filing/0001821825-22-000002.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"uch as patient adherence programs that can further drive value in collaboration with Organon's trade partners. Organon does not have any single customer that, if such customer were lost, would have a material adverse effect on Organon's business. Distribution Organon's global network enables it to distribute products directly and indirectly to patients in more than 140 countries and territories, including through Organo","filed_date":"2022-03-21","accession":"0001821825-22-000002","full_text":"https://origin.rootz.global/static/filing/0001821825-22-000002.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":13,"context":"f sales | 583 | | | 460 | | | 1,174 | | | 998 | | | | Selling, general and administrative | 416 | | | 284 | | | 798 | | | 601 | | | | Research and development | 76 | | | 51 | | | 143 | | | 96 | | | | Restructuring costs | 1 | | | 19 | | | 2 | | | 31 | | | | Other (income) expense, net | 82 | | | 10 | | | 80 | | | 34 | | | | | 1,158 | | | 824 | | | 2,197 | | | 1,760 | | | | Income From Continuing Operations Before In","filed_date":"2021-08-16","accession":"0001821825-21-000009","full_text":"https://origin.rootz.global/static/filing/0001821825-21-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":13,"context":"ling, general and administrative | 434 | 453 | 858 | 873 | | | Research and development | 90 | 95 | 183 | 191 | | | Acquired in-process research and development and milestones | 1 | | 1 | 6 | | | | | Restructuring costs | | 2 | 31 | 88 | | | Interest expense | 108 | 131 | 219 | 255 | | | Exchange losses (gains) | 2 | (1) | 9 | (5) | | | Other expense (income), net | 29 | (35) | (67) | (23) | | | Income before income","filed_date":"2026-07-31","accession":"0001628280-26-051230","full_text":"https://origin.rootz.global/static/filing/0001628280-26-051230.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":96,"match_count":12,"context":"(ii) pursuing product divestiture transactions that will strengthen our balance sheet and create future growth opportunities and (iii) decreasing our cost structure. Our efforts included implementing restructuring initiatives aimed at driving operational efficiencies and cost savings initiatives and reducing our outstanding long-term debt. In pursuit of our strategy, in January 2026, we divested the Jada System to Labori","filed_date":"2026-02-24","accession":"0001628280-26-011125","full_text":"https://origin.rootz.global/static/filing/0001628280-26-011125.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":96,"match_count":12,"context":"s | 609 | | | 535 | | | 1,783 | | | 1,533 | | | | Selling, general and administrative | 388 | | | 321 | | | 1,186 | | | 922 | | | | Research and development | 111 | | | 54 | | | 254 | | | 150 | | | | Restructuring costs | 1 | | | 12 | | | 3 | | | 43 | | | | Other (income) expense, net | 102 | | | 10 | | | 182 | | | 44 | | | | | 1,211 | | | 932 | | | 3,408 | | | 2,692 | | | | Income From Continuing Operations Before","filed_date":"2021-11-12","accession":"0001628280-21-023199","full_text":"https://origin.rootz.global/static/filing/0001628280-21-023199.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":88,"match_count":11,"context":"rative | | | 1,760 | | | 1,893 | | (7) | | | | Research and development | | | 469 | | | 528 | | (11) | | | | Acquired in-process research and development and milestones | | | 81 | | | 8 | | * | | | | Restructuring costs | | | 31 | | | 62 | | (50) | | | | Interest expense | | | 520 | | | 527 | | (1) | | | | Exchange losses | | | 26 | | | 42 | | (38) | | | | Other expense, net | | | 21 | | | 15 | | 40 | | | ** Calcula","filed_date":"2025-11-10","accession":"0001104659-25-108693","full_text":"https://origin.rootz.global/static/filing/0001104659-25-108693.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":88,"match_count":11,"context":"In July 2022, entered into a research collaboration and license agreement with Cirqle Biomedical (\"Cirqle\") for a novel investigational non-hormonal, on-demand contraceptive candidate. In June 2022, entered into a licensing agreement with Henlius, for commercialization rights for biosimilar candidates HLX11, referencing Perjeta (pertuzumab), used for the treatment of certain patients with HER2+ breast cancer in combinations with","filed_date":"2023-02-27","accession":"0001821825-23-000003","full_text":"https://origin.rootz.global/static/filing/0001821825-23-000003.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":80,"match_count":10,"context":"aintaining an external manufacturing network. Our manufacturing network and supply chains are designed to provide us with a flexible and scalable global platform for continued expansion, including in emerging markets. The United States has imposed or is considering imposing trade protection measures and import or export licensing requirements, including the direct and indirect impacts of tariffs (including pharm","filed_date":"2026-02-24","accession":"0001628280-26-011125","full_text":"https://origin.rootz.global/static/filing/0001628280-26-011125.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":80,"match_count":10,"context":"g, general and administrative | 415 | 422 | 1,288 | 1,290 | | | Research and development | 84 | 111 | 275 | 339 | | | Acquired in-process research and development and milestones | | 51 | 6 | 81 | | | Restructuring costs | | | 88 | 23 | | | Interest expense | 128 | 126 | 383 | 388 | | | Exchange losses | 17 | 6 | 12 | 11 | | | Other (income) expense, net | (30) | | (53) | 9 | | | Income before income taxes | 243 | 20","filed_date":"2025-11-10","accession":"0001628280-25-050795","full_text":"https://origin.rootz.global/static/filing/0001628280-25-050795.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"|  10,000 |  | | |  | |  Annual Equity Retainer(2) |  |  $ |  200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | |  (1) |  Annual cash retainers are payable in quarterly installments to each director. The Independent Chairman of the Board cash retainer includes the Non-Employee Director cash retainer fee of $120,000. | | |  (2) |  The Annual equity retainer is delivered in th","filed_date":"2024-04-25","accession":"0001193125-24-114048","full_text":"https://origin.rootz.global/static/filing/0001193125-24-114048.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":72,"match_count":9,"context":"lling, general and administrative | 453 | 437 | 873 | 868 | | | Research and development | 95 | 116 | 191 | 228 | | | Acquired in-process research and development and milestones | | 15 | 6 | 30 | | | Restructuring costs | 2 | | 88 | 23 | | | Interest expense | 131 | 131 | 255 | 262 | | | Exchange (gains) losses | (1) | (1) | (5) | 5 | | | Other (income) expense, net | (35) | 6 | (23) | 9 | | | Income before income t","filed_date":"2025-08-06","accession":"0001821825-25-000066","full_text":"https://origin.rootz.global/static/filing/0001821825-25-000066.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":72,"match_count":9,"context":"ative | 1,760 | 1,893 | 1,704 | (7) | 11 | | | Research and development | 469 | 528 | 471 | (11) | 12 | | | Acquired in-process research and development and milestones | 81 | 8 | 107 | * | (93) | | | Restructuring costs | 31 | 62 | 28 | (50) | * | | | Interest expense | 520 | 527 | 422 | (1) | 25 | | | Exchange losses | 26 | 42 | 11 | (38) | * | | | Other expense, net | 21 | 15 | 15 | 40 | | | * Calculation not mean","filed_date":"2025-02-28","accession":"0001821825-25-000006","full_text":"https://origin.rootz.global/static/filing/0001821825-25-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":72,"match_count":9,"context":"ity, technology and procurement capabilities. Our manufacturing network and supply chains are designed to provide us with a flexible and scalable global platform for continued expansion, including in emerging markets. Quality Management Our facilities and supporting functions, along with our external contractors, suppliers and partners, make up an integrated, interdependent global network. This network is dedica","filed_date":"2025-02-28","accession":"0001821825-25-000006","full_text":"https://origin.rootz.global/static/filing/0001821825-25-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":72,"match_count":9,"context":"strative | 1,893 | 1,704 | 1,668 | 11 | 2 | | | Research and development | 528 | 471 | 339 | 12 | 39 | | | Acquired in-process research and development and milestones | 8 | 107 | 104 | (93) | 3 | | | Restructuring costs | 62 | 28 | 3 | * | * | | | Interest expense | 527 | 422 | 258 | 25 | 64 | | | Exchange losses | 42 | 11 | 4 | * | * | | | Other expense, net | 15 | 15 | 17 | | (12) | | | $ | 5,590 | $ | 5,052 | $ |","filed_date":"2024-02-26","accession":"0001628280-24-006733","full_text":"https://origin.rootz.global/static/filing/0001628280-24-006733.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"platform_shift","strength":72,"match_count":9,"context":"ity, technology and procurement capabilities. Our manufacturing network and supply chains are designed to provide us with a flexible and scalable global platform for continued expansion, including in emerging markets. Quality Management Our facilities and supporting functions, along with our external contractors, suppliers, and partners, make up an integrated, interdependent global network. This network is dedic","filed_date":"2024-02-26","accession":"0001628280-24-006733","full_text":"https://origin.rootz.global/static/filing/0001628280-24-006733.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":72,"match_count":9,"context":"Other | | | | | | | | | | Cost of sales (2) | 591 | | | 538 | | | | | | | | Selling, general and administrative | 382 | | | 317 | | | | | | | | Research and development | 67 | | | 45 | | | | | | | | Restructuring costs | 1 | | | 12 | | | | | | | | Other (income) expense, net | (2) | | | 24 | | | | | | | | | 1,039 | | | 936 | | | | | | | | Income From Continuing Operations Before Income Taxes | 467 | | | 844 | | | |","filed_date":"2021-06-21","accession":"0001821825-21-000005","full_text":"https://origin.rootz.global/static/filing/0001821825-21-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":64,"match_count":8,"context":"ction; (B) is not and will not become a party to any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity: (1) as to how the person, if elected as a director, will act or vote on any issue or question that has not been disclosed to the Corporation; or (2) that could limit or interfere with the persons ability to comply, if elected as a director, with such","filed_date":"2022-12-09","accession":"0001104659-22-125576","full_text":"https://origin.rootz.global/static/filing/0001104659-22-125576.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":64,"match_count":8,"context":"zumab-gnlm) and Vtama (tapinarof) cream 1%. Many brands in the established brands portfolio lost exclusivity years ago and have faced generic competition for some time. On April 26, 2026, the Company entered into a definitive agreement with Sun Pharmaceutical Industries Limited (Sun Pharma) under which Sun Pharma will acquire all of the Companys outstanding shares of common stock for $14.00 per share in cash. Completion of the tran","filed_date":"2026-07-31","accession":"0001628280-26-051230","full_text":"https://origin.rootz.global/static/filing/0001628280-26-051230.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":57,"match_count":4,"context":"entory levels, this could contribute to our quarterly and/or annual revenue failing to meet our expectations.Recent health care reform initiatives focused on the cost of prescription drugs may have a material adverse effect on our business and results of operations.Governments globally, as well as payors in the U.S., are increasingly using a variety of measures to control costs, including, among others, legislative or r","filed_date":"2025-11-10","accession":"0001628280-25-050795","full_text":"https://origin.rootz.global/static/filing/0001628280-25-050795.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":56,"match_count":7,"context":"profit | 841 | 957 | | | | | Selling, general and administrative | 420 | 431 | | | Research and development | 96 | 112 | | | Acquired in-process research and development and milestones | 6 | 15 | | | Restructuring costs | 86 | 23 | | | Interest expense | 124 | 131 | | | Exchange (gains) losses | (4) | 6 | | | Other expense, net | 12 | 3 | | | Income before income taxes | 101 | 236 | | | Income tax expense | 14 | 35","filed_date":"2025-05-02","accession":"0001821825-25-000023","full_text":"https://origin.rootz.global/static/filing/0001821825-25-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"|  |  |  |  |  |  |  |  |  |  | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | |  | |  (1) |  Annual cash retainers are payable in quarterly installments to each director. The Independent Chairman of the Board cash retainer includes the Non-Employee Director cash retainer fee of $120,000. |  | |  (2) |  The Annual equity retainer is delivered in t","filed_date":"2025-04-25","accession":"0000950170-25-058795","full_text":"https://origin.rootz.global/static/filing/0000950170-25-058795.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"|  |  |  |  |  |  | | |  Annual Equity Retainer(2) |  |  $ |  200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | |  (1) |  Annual cash retainers are payable in quarterly installments to each director. The Independent Chairman of the Board cash retainer includes the Non-Employee Director cash retainer fee of $120,000. | | |  (2) |  Annual equity retainer is delivered in the fo","filed_date":"2023-04-27","accession":"0001193125-23-122171","full_text":"https://origin.rootz.global/static/filing/0001193125-23-122171.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"e or electing payment upon separation from service (or a date up to 15 years following separation from service), and in either case may elect to receive their accounts in a lump sum or in annual installments over a period of up to 15 years. With respect to each years contributions and imputed earnings, the participant may make a separate distribution election. All distributions from the directors def","filed_date":"2022-04-28","accession":"0001193125-22-127598","full_text":"https://origin.rootz.global/static/filing/0001193125-22-127598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":56,"match_count":7,"context":"on Organon's common stock that was paid on September 13, 2021 to stockholders of record at the close of business on August 23, 2021. 20.Subsequent Events In November 2021, Organon and Forendo Pharma entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in womens health. Forendo is pioneering the science of intracrinology, addressing dise","filed_date":"2021-11-12","accession":"0001628280-21-023199","full_text":"https://origin.rootz.global/static/filing/0001628280-21-023199.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":53,"match_count":6,"context":"standalone company, Organon has expanded its women's health portfolio through four acquisitions:  Acquired Alydia Health, a commercial stage company focused on the treatment of postpartum hemorrhage. Entered into a licensing agreement with ObsEva for the global development, manufacturing and commercial rights to ebopiprant (OBE022), an investigational agent being evaluated as a potential treatment for preterm labor. -3- [Table of","filed_date":"2022-03-21","accession":"0001821825-22-000002","full_text":"https://origin.rootz.global/static/filing/0001821825-22-000002.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"OGN","company":"Organon & Co.","exchange":"NYSE","sector":"Pharmaceutical Preparations","signal_type":"margin_pressure","strength":48,"match_count":6,"context":"and other U.S. and comparable government agencies; difficulties and uncertainties inherent in the implementation of our acquisition strategy or failure to recognize the benefits of such acquisitions; pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to or affecting Medicare, Medicaid and health care reform, pharmaceut","filed_date":"2025-11-10","accession":"0001628280-25-050795","full_text":"https://origin.rootz.global/static/filing/0001628280-25-050795.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"9c5f33edbcadf5448e9d454a14f442325c103c74ef288e931533e40d22d62ec4","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"df19c9b25279485c41eaa8d397281be31b04336faed4c9a9784e125ba4c48603","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":172,"hourly_limit":500,"remaining":328,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}